Publications by authors named "Dario Formica"
This real-world analysis was performed on administrative databases to evaluate characteristics, therapies, and related economic burden of glaucoma in Italy. Adults with at least 1 prescription for ophthalmic drops (ATC class S01E: antiglaucoma preparations, miotics) during data availability period (January 2010-June 2021) were screened, then patients with glaucoma were included. First date of ophthalmic drops prescription was the index date.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the costs associated with treating anemia in chronic kidney disease (CKD) patients using erythropoiesis-stimulating agents (ESAs) and explored how to reduce these costs through increased use of biosimilars and by preventing inappropriate ESA use.
- Data was collected from five geographic areas in Italy, with annual healthcare costs analyzed for different stages of CKD, showing that ESA-related costs accounted for a significant portion of overall healthcare expenses.
- Results indicated that adopting biosimilars could save up to 10.5% of ESA costs, while preventing inappropriate ESA treatment could lead to additional significant savings, thereby stressing the importance of cost-effective strategies in managing CKD.